Erschienen in:
01.03.2000 | Meeting abstract
Herceptin™ (trastuzumab) in patients who overexpress Her-2 and have failed multiple chemotherapy regimens for advanced breast cancer: a pragmatic study
verfasst von:
G Westman
Erschienen in:
Breast Cancer Research
|
Sonderheft 1/2000
Einloggen, um Zugang zu erhalten
Excerpt
This prospective study will include patients who are at least 18 years of age, with a histologically or cytologically confirmed diagnosis of advanced breast cancer (ABC), who have failed or are resistant to treatment with at least two chemotherapy regimens for ABC, and who overexpress HER-2. A maximum of 62 patients are to be included for the detection of an overall response rate of 20% (10-30%, 95% confidence interval). …